Genmab A/S (OTCMKTS:GNMSF - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $209.92 and traded as low as $200.00. Genmab A/S shares last traded at $200.00, with a volume of 199 shares traded.
Genmab A/S Stock Up 3.6 %
The company has a market capitalization of $13.49 billion, a PE ratio of 11.66 and a beta of 1.10. The company's 50 day moving average is $202.85 and its two-hundred day moving average is $208.87.
Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $5.70 EPS for the quarter, beating the consensus estimate of $0.46 by $5.24. Genmab A/S had a net margin of 36.30% and a return on equity of 19.75%.
About Genmab A/S
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Articles
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
